Pluvicto?

Pluvicto™ (Lutetium‑177 vipivotide tetraxetan)
—A radioligand therapy for advanced prostate cancer

---

1. What is Pluvicto?

• Drug class: Radiopharmaceutical (lutetium‑177–labelled peptide) that targets the prostate‑specific membrane antigen (PSMA) on prostate cancer cells.
• Brand name: Pluvicto™
• Generic name: Lutetium‑177 vipivotide tetraxetan
• Approval: FDA‑approved in 2022; also approved in the EU (EMA) and many other regions.

---

2. Who is it used for?

• Indication: Men with metastatic castration‑resistant prostate cancer (mCRPC) that is PSMA‑positive (confirmed by a PSMA PET/CT scan) after treatment with:

  1. An androgen‑receptor (AR) pathway inhibitor, and
  2. A taxane‑based chemotherapy regimen (e.g., docetaxel or cabazitaxel).

• Why PSMA‑positive? PSMA is a protein overexpressed on the surface of most prostate cancer cells. Pluvicto binds to this protein and delivers targeted beta radiation, sparing most normal tissues.

---

3. How is it given?

• Route: Intravenous infusion.
• Dose schedule:
  • Standard: 6.4 GBq (≈173 mCi) per cycle.
  • Cycles: Up to 6 cycles, each separated by 6‑8 weeks (depending on the treating physician and patient tolerance).
• Administration setting: Outpatient infusion center; requires monitoring for radiation safety and patient‑specific precautions (e.g., limiting close contact with others for a short period post‑infusion).

---

4. How does it work?

1. Targeting – The vipivotide peptide has a high affinity for PSMA.
2. Binding – Once bound, the lutetium‑177 emits beta particles (high‑energy radiation).
3. Cell killing – The radiation damages the DNA of cancer cells, leading to cell death while sparing surrounding tissues that do not express PSMA.

---

5. What are the main side effects?

System	Common / Notable AEs	Management Tips
Hematologic	Neutropenia, thrombocytopenia, anemia	CBC monitoring; consider growth factors or dose modifications.
GI	Nausea, vomiting, diarrhea, decreased appetite	Antiemetics; dietary adjustments; hydration.
Salivary	Xerostomia (dry mouth)	Use saliva substitutes; stay hydrated.
General	Fatigue, fever, chills	Rest; antipyretics.
Others	Rare: alopecia, rash, alopecia	Symptom‑specific care.
Long‑term	Potential secondary cancers, renal toxicity	Long‑term surveillance; baseline renal function assessment.

---

6. Contraindications & Precautions

• Pregnancy & breastfeeding – Not for use; can harm fetus/infant.
• Renal impairment – Dose adjustments may be required; monitor creatinine.
• Bone marrow suppression – Contraindicated in severe cytopenias.
• Active infections – May need to be treated before starting.

Special precautions:

• Radiation safety – Patients must follow post‑infusion guidelines (e.g., avoiding close contact for 24–48 h, limiting time in public).
• Concurrent medications – Avoid agents that suppress bone marrow or affect renal clearance unless the benefits outweigh the risks.

---

7. Drug interactions

Interaction	Potential Issue	How to manage
Other myelosuppressive drugs	Additive bone marrow toxicity	Dose adjustments or hold overlapping therapy.
Renally cleared agents	Elevated exposure	Monitor renal function; adjust dose.
Radiation‑sparing drugs	Potentially reduced efficacy	Evaluate on a case‑by‑case basis.

---

8. What should patients expect during treatment?

• Pre‑infusion: Baseline blood counts, kidney function, and a PSMA PET/CT.
• Infusion time: ~30–60 minutes.
• Post‑infusion: Stay in the infusion center for a short observation period; then follow safety instructions (e.g., no close contact with pregnant/baby for a few hours).
• Follow‑up: CBC every 2–4 weeks, imaging to assess tumor response, and periodic safety labs.

---

9. FAQs

Question	Answer
Is Pluvicto an oral medication?	No, it is given by IV infusion.
Can it be used as first‑line therapy?	Currently indicated after AR inhibitors + taxane chemotherapy.
Will it cure prostate cancer?	It is a systemic therapy that can prolong survival and control disease but is not curative.
Are there other radioligand therapies?	Yes—Lutathera® (177Lu‑DOTATATE) for neuroendocrine tumors; and 177Lu‑PSMA‑617 is a competitor.
Can I get it in the U.S.?	Yes, it is FDA‑approved and available through specialized oncology centers.

---

10. Bottom line

Pluvicto is a cutting‑edge, targeted radiopharmaceutical that delivers lethal radiation directly to PSMA‑positive prostate cancer cells while sparing most healthy tissues. It is used after standard systemic therapies in men with metastatic castration‑resistant disease. As with all radiopharmaceuticals, careful patient selection, monitoring, and radiation safety measures are essential.

If you or a loved one has been offered Pluvicto, talk to your oncologist about the potential benefits and risks in the context of your overall treatment plan. Feel free to ask me any more specific questions—whether about side‑effect management, scheduling, or insurance coverage!